Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139

Benzinga · 2d ago
Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $133 to $139.